Weekly AI-generated video check-ins for people with psoriasis
Compares AI video visits, human video calls, and usual care in psoriasis.
Plain-language title generated from the registry record
Registry title: Assessing Psoriasis Treatment Outcomes
Key facts
- Where
- Winston-Salem, United StatesSee the site
Where in United States
- Wake Forest University Health Sciences Department of DermatologyWinston-Salem, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT07391423
- Record updated
- 5 November 2026
- Original description
To assess the feasibility of AIGPP video interactions with psoriasis patients. To explore patient attitudes, trust, and comfort levels concerning AIGPP interactions in a healthcare setting, and to understand their influence on the patient-physician dynamic. To evaluate medication adherence over a 4-week period in patients with psoriasis randomized to weekly AI-generated automated physician providers (AIGPP) video interactions, weekly human video calls, or standard care (single follow up visit after 4 weeks). Adherence rates will be evaluated via a cap designed to record adherence attached to the study medication container.Read full original descriptionShow less
Assessing Psoriasis Treatment Outcomes: a Single-center, Prospective Study Evaluating Patient Outcomes in Psoriasis
To assess the feasibility of AIGPP video interactions with psoriasis patients. To explore patient attitudes, trust, and comfort levels concerning AIGPP interactions in a healthcare setting, and to understand their influence on the patient-physician dynamic. To evaluate medication adherence over a 4-week period in patients with psoriasis randomized to weekly AI-generated automated physician providers (AIGPP) video interactions, weekly human video calls, or standard care (single follow up visit after 4 weeks). Adherence rates will be evaluated via a cap designed to record adherence attached to the study medication container.
Inclusion: Patients ≥18 years of age; Patients with a current diagnosis of psoriasis suitable for treatment with topical Betamethasone (BD); Patients who live in the United States; Patients with a sufficient command of the English language; Patients with a mobile device able to at least operate at 25 frames per second (FPS).
Exclusion: Patients that are taking concomitant topical or systemic therapy for the treatment of psoriasis and/or phototherapy; Patients without a current diagnosis of psoriasis suitable for treatment with topical BD; Patients with severe or unstable comorbid conditions; Patients with any other skin conditions that prohibit or confound the ability of the investigator to interpret skin findings; Patients less than the age of 18; Patient who are pregnant or breastfeeding; Patients without mobile devices able to at least operate at 25 frames per second (FPS).